I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...

I-Mab (IMAB) stock jumped 15% Monday after the biotech company said it plans to focus on developing givastomig for the treatment of gastric cancers. Read more here.

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving beyond cancer and rare disease.

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Twins are pretty rare, accounting for just 3% of births in the U.S. these days. But new research shows that for primates 60 million years ago, giving birth to twins was the norm.

US top doctor calls for cancer warnings on alcohol; see the 7 types of cancers at risk 04-01-25 ...

As Bulgaria joined Europe's borderless travel zone on January 1st, Greeks have been freely flocking to the neighboring country, where petrol prices are cheaper, to fill up their tanks. Bulgaria, along ...